Gastroesophageal reflux disease (GERD) is a condition in which gastric contents and acid flow up from the stomach into the esophagus (food pipe) due to poor stomach emptying, poor valve function, and problems with the esophagus.
Frequent and mild gastroesphageal reflux (GER) is quite common, especially in infants, but the disease (GERD) is more severe and causes complications.
About half of American adults experience GERD at least once a month.
The hallmark symptoms of GERD may occur several times per day and include:
Typical GERD symptoms in infants include frequent regurgitation, irritability, arching the back, choking or gagging, and resisting feedings.
Gastroesophageal reflux disease (GERD) is a condition in which acid from the stomach flows back up into the esophagus (the food pipe), a situation called
The hallmark symptoms of GERD are:
Although acid is a primary factor in damage caused by GERD, other products of the digestive tract, including pepsin and bile, can also be harmful.
Heartburn is a condition in which the acidic stomach contents back up into the esophagus, causing pain in the chest area. This reflux usually occurs because the sphincter muscle between the esophagus and stomach is weakened. Remaining upright by standing or sitting up after eating a meal can help reduce the reflux that causes heartburn. Continuous irritation of the esophagus lining, as in severe GERD, is a risk factor for developing esophageal cancer.
The esophagus, commonly called the food pipe, is a narrow muscular tube about 9.5 inches long. It begins below the tongue and ends at the stomach. The esophagus is narrowest at the top and bottom; it also narrows slightly in the middle.
The esophagus consists of 3 basic layers:
When a person swallows food, the esophagus moves it into the stomach through the action of wave-like muscle contractions, called peristalsis. In the stomach, acid and various enzymes break down the starch, fat, and protein in food. The lining of the stomach has a thin layer of mucus that protects it from these fluids.
However, if acid and enzymes back up into the esophagus, its lining offers only a weak defense against these substances. Instead, several other factors protect the esophagus. The most important structure protecting the esophagus may be the
If the pressure barrier is not enough to prevent regurgitation and acid backs up (reflux), peristaltic action of the esophagus serves as an additional defense mechanism, pushing the backed-up contents back down into the stomach.
Anyone who eats a lot of acidic foods can have mild and temporary heartburn. This is especially true when lifting, bending over, or lying down after eating a large meal high in fatty, acidic foods. However, persistent GERD may be due to various conditions, including biological or structural problems.
The band of muscle tissue called the LES is responsible for closing and opening the lower end of the esophagus, and is essential for maintaining a pressure barrier against contents from the stomach. For it to function properly, there needs to be interaction between smooth muscles and various hormones. If it weakens and loses tone, the LES cannot close completely after food empties into the stomach, and acid from the stomach backs up into the esophagus. Dietary substances, drugs, and nervous system factors can weaken the LES and impair its function.
People with GERD may have abnormal nerve or muscle function in the stomach. These abnormalities prevent the stomach muscles from contracting normally, which causes delays in stomach emptying, and increasing the risk for acid back-up.
Some studies suggest that most people with atypical GERD symptoms (such as hoarseness, chronic cough, or the feeling of having a lump in the throat) have specific abnormalities in the esophagus.
A hiatal hernia occurs when part of the stomach protrudes up into the chest through the sheet of muscle called the diaphragm. This may result from a weakening of the surrounding tissues and may be aggravated by obesity or smoking.
About 30 to 40% of reflux is most likely hereditary, according to several twin and family studies. An inherited risk exists in many cases of GERD, possibly because of inherited muscular or structural problems in the stomach or esophagus. Genetic factors may play an especially strong role in susceptibility to Barrett esophagus, a precancerous condition caused by very severe GERD.
Crohn disease is a chronic ailment that causes inflammation and injury in the small intestine, colon, and other parts of the gastrointestinal tract, sometimes including the esophagus. Other disorders that may contribute to GERD include diabetes, any gastrointestinal disorder (including peptic ulcers), lymphomas, and other types of cancer.
Helicobacter pylori, also called H. pylori, is a bacterium that is sometimes found in the mucus membranes of the stomach. It is now known to be a major cause of peptic ulcers. Antibiotics that eradicate H. pylori are an accepted treatment for preventing and curing ulcers.
The role of H. pylori in causing GERD is less clear. It may depend on what portion of the stomach is involved. Although in some patients, treating H. pylori may actually worsen symptoms, in general treating H. pylori is unlikely to worsen GERD.
About half of American adults experience GERD at least once a month. People of all ages are susceptible to GERD. Elderly people with GERD tend to have a more serious condition than younger people.
People who eat a heavy meal and then lie on their back or bend over from the waist are at risk for an attack of heartburn. Anyone who snacks at bedtime is also at high risk for heartburn.
Pregnant women are particularly vulnerable to GERD in their third trimester, as the growing uterus puts increasing pressure on the stomach. Heartburn in such cases is often resistant to dietary interventions and even to antacids.
A number of studies suggest that obesity contributes to GERD, and it may increase the risk for severe inflammation in the esophagus in people with GERD. Having excess abdominal fat may be the most important risk factor for the development of acid reflux and associated complications, such as Barrett's esophagus and cancer of the esophagus. Losing weight appears to help reduce GERD symptoms.
People with asthma are at very high risk for GERD. Between 50 and 90% of people with asthma have some symptoms of GERD. People with chronic obstructive pulmonary disease (COPD) are also at increased risk for GERD, and having GERD may worsen pre-existing COPD.
Increasing evidence indicates that smoking raises the risk for GERD. Smoking reduces LES muscle function, increases acid secretion, impairs muscle reflexes in the throat, and damages protective mucus membranes. Smoking reduces salivation, and saliva helps neutralize acid. It is unknown whether the smoke, nicotine, or both trigger GERD. For example, some people who use nicotine patches to quit smoking have heartburn, but it is not clear whether the nicotine or stress produces the acid backup. In addition, smoking can lead to emphysema, a form of COPD, which is itself a risk factor for GERD.
Alcohol has mixed effects on GERD. It relaxes the LES muscles and, in high amounts, may irritate the mucus membrane of the esophagus. Small amounts of alcohol, however, may actually protect the mucosal layer.
It should be noted that a combination of heavy alcohol use and smoking increases the risk for esophageal cancer.
Symptoms of GERD are more likely to occur in postmenopausal women who receive hormone replacement therapy. The risk increases with larger estrogen doses and longer duration of therapy.
Heartburn is the primary symptom of GERD. It is a burning sensation that spreads up from the stomach to the chest and throat. Heartburn is most likely to occur in connection with the following activities:
People with nighttime GERD, a common problem, tend to feel more severe pain than those whose symptoms occur at other times of the day.
The severity of heartburn does not necessarily indicate actual injury to the esophagus. For example, Barrett's esophagus, which causes precancerous changes in the esophagus, may only trigger a few symptoms, especially in elderly people. On the other hand, people can have severe heartburn but suffer no damage to their esophagus.
Nearly half of people with GERD have dyspepsia, a syndrome that consists of:
People without GERD can also have dyspepsia.
Regurgitation is the feeling of acid backing up in the throat. Sometimes acid regurgitates as far as the mouth and can be experienced as a "wet burp." Uncommonly, it may come out forcefully as vomit.
Many people with GERD do not have heartburn or regurgitation. Elderly people with GERD often have less typical symptoms than do younger people. Instead, symptoms may occur in the mouth or lungs.
People may have the sensation that food is trapped behind the breastbone. Chest pain is a common symptom of GERD. It is very important to differentiate it from chest pain caused by heart conditions, such as angina and heart attack.
Less commonly, GERD may produce symptoms that occur in the throat, including:
Airway symptoms, such as coughing and wheezing, may occur.
Nausea that persists for weeks or even months, and is not traced back to a common cause of stomach upset, may be a symptom of acid reflux. In rare cases, vomiting can occur as often as once a day. All other causes of chronic nausea and vomiting should be ruled out, including ulcers, stomach cancer, obstruction, and pancreas or gallbladder disorders.
GER is very common in children of all ages, but it is usually mild. Symptoms usually get better in most infants by age 12 months, and in nearly all children by 24 months. Children with the following conditions are at higher risk for true GERD:
Typical reflux symptoms in infants include:
A physician should examine any child who has symptoms of severe GERD as soon as possible, because these symptoms may lead to complications such as anemia, failure to gain weight, or respiratory problems. Symptoms of severe GERD in infants and small children may include:
These symptoms may be related to other causes. Babies and children may experience these symptoms without having GERD.
In addition, many infants with normal irritability are being inappropriately treated for reflux disorders.
Nearly everyone has an attack of heartburn at some point in their lives. In the vast majority of cases the condition is temporary and mild, causing only short-term discomfort. If people develop persistent GERD with frequent relapses, and it remains untreated, serious complications may develop over time. Complications can include:
Older people are at higher risk for complications from persistent GERD. The following conditions also put individuals at risk for recurrent and serious GERD:
Despite the complications that can occur with the condition, GERD does not appear to shorten life expectancy.
Erosive esophagitis develops in people with chronic GERD when acid irritation and inflammation cause extensive injuries to the esophagus. The longer and more severe the GERD, the higher the risk for developing erosive esophagitis.
Bleeding may occur in about 8% of people with erosive esophagitis. In very severe cases, people may have dark-colored, tarry stools (indicating the presence of blood) or may vomit blood, particularly if ulcers have developed in the esophagus. This is a sign of severe damage and requires immediate attention.
Sometimes long-term bleeding can result in iron-deficiency anemia and may even require emergency blood transfusions. This condition can occur without heartburn or other warning symptoms, or even without obvious blood in the stools.
Barrett esophagus is a disorder in which the lining of the esophagus is damaged by stomach acid. The lining becomes similar to that of the stomach. These changes place a person at risk for esophageal cancer.
Only 10% of people with symptomatic GERD have Barrett esophagus. While obesity, alcohol use, and smoking have all been implicated as risk factors for Barrett esophagus, their role remains unclear. Only the persistence of GERD symptoms indicates a higher risk for Barrett esophagus.
Not all people with Barrett esophagus have either esophagitis or symptoms of GERD. Most likely, more than half of people with the condition have no GERD symptoms at all. Barrett esophagus, then, is likely to be much more common and probably less harmful than is currently believed.
The incidence of esophageal cancer is higher in people with Barrett esophagus. When people with Barrett esophagus develop abnormal changes of the mucus membrane cells lining the esophagus (dysplasia), the risk of cancer rises significantly. There is some evidence that acid reflux may contribute to the development of cancer in Barrett's esophagus. Still, only a minority of people with Barrett esophagus develop cancer.
Some experts recommend that people with Barrett esophagus who also have other risk factors for esophageal cancer undergo endoscopic screening every 3 to 5 years. Destroying any abnormal cells (dysplasia) with heat, cold, laser, or other methods is the treatment of choice.
If the esophagus becomes severely injured over time, narrowed regions called
Asthma and GERD often occur together. Some theories about the connection between GERD and asthma are:
There is some evidence that asthma triggers GERD, but in people who have both conditions, treating GERD does not appear to improve asthma.
Studies indicate an association between GERD and various upper respiratory problems that occur in the sinuses, ear and nasal passages, and airways of the lung. People with GERD appear to have an above-average risk for chronic bronchitis, chronic sinusitis, emphysema, pulmonary fibrosis (lung scarring), and recurrent pneumonia. If a person inhales fluid from the esophagus into the lungs, serious pneumonia can occur. It is not yet known whether treating GERD would also reduce the risk for these respiratory conditions.
Dental erosion (the loss of the tooth's enamel coating) is a very common problem among people with GERD, including children. It results from acid backing up into the mouth and wearing away the tooth enamel.
An estimated 20 to 60% of people with GERD have symptoms in the throat (hoarseness, sore throat) without any significant heartburn. A failure to diagnose and treat GERD may lead to persistent throat conditions, such as chronic laryngitis, hoarseness, difficulty speaking, sore throat, cough, constant throat clearing, and granulomas (soft, pink bumps) on the vocal cords.
GERD commonly occurs with obstructive sleep apnea, a condition in which breathing stops temporarily many times during sleep. Sleep apnea may develop in infants, children, or adults with GERD. It is not clear which condition is responsible for the other, but GERD is particularly severe when both conditions occur together. In adults, the 2 conditions may have risk factors in common, such as obesity and sleeping on the back. Studies suggest that in adults with sleep apnea, GERD can be markedly improved with a continuous positive airway pressure (CPAP) device, which opens the airways and is the standard treatment for severe sleep apnea.
Children with GERD tend to refuse food and may be late in eating solid foods.
In addition to asthma, GERD is associated with other upper airway problems, including ear infections and sinusitis.
Infants and children with GERD are at higher risk for sleep apnea.
The following complications only occur in rare cases:
The infant's life may be in danger if acid reflux causes spasms in the larynx severe enough to block the airways. Some experts believe this chain of events may contribute to sudden infant death syndrome (SIDS). More research is needed to determine whether this association is valid.
A person with
Laboratory or more invasive tests, including endoscopy, may be required if:
Some of these tests are described below.
A barium swallow radiograph (x-ray) is useful for identifying structural abnormalities and erosive esophagitis. For this test, the patient drinks a solution containing barium, and then x-rays of the digestive tract are taken. This test can show stricture, active ulcer craters, hiatal hernia, erosion, or other abnormalities. However, it cannot reveal mild irritation.
Upper endoscopy, also called esophagogastroduodenoscopy or panendoscopy, is more accurate than a barium swallow radiograph. It is also more invasive and expensive. It is widely used in GERD for identifying and grading severe esophagitis, monitoring people with Barrett esophagus, or when other complications of GERD are suspected. Upper endoscopy is also used as part of various surgical techniques.
Guidelines from the American Gastroenterological Association do not recommend endoscopy screening for everyone with chronic GERD because there is no evidence that it can improve survival rates for cancer.
The American College of Physicians recommends upper endoscopy in:
Endoscopy may be performed either in a hospital or doctor's office:
Complications from the procedure are uncommon. If they occur, complications are usually mild and typically include minor bleeding from the biopsy site or irritation where medications were injected.
If a person has moderate-to-severe GERD symptoms and the procedure reveals injury in the esophagus, usually no further tests are needed to confirm a diagnosis. The test is not foolproof, however. A visual view misses about half of all esophageal abnormalities.
In this test, the person swallows a small capsule containing a tiny camera. Then, a series of color pictures are transmitted to a recording device where they can be downloaded and interpreted by a doctor. The entire procedure takes 20 minutes. The capsule is naturally passed through the digestive system within 24 hours. A newer technique has a string attached to the capsule for retrieval. Capsule endoscopy may provide a less invasive alternative to traditional endoscopy. However, while capsule endoscopy is useful as a screening device for diagnosing esophageal conditions such as GERD and Barrett esophagus, traditional endoscopy is still required for obtaining tissue samples.
Barrett's esophagus is diagnosed using endoscopy.
Periodic endoscopy is recommended for detecting cancer at an earlier stage in people who have been diagnosed with Barrett esophagus. When Barrett esophagus is diagnosed, multiple biopsies are generally taken. The biopsy results will determine the frequency of future monitoring. Unfortunately, monitoring people with Barrett esophagus has not been proven to change overall mortality rates from esophageal cancer.
The (ambulatory) pH monitor examination may be used to determine acid backup. It is useful when endoscopy has not detected damage to the mucus lining in the esophagus, but GERD symptoms are present. pH monitoring may be used when people have not found relief from medicine or surgery. Traditional trans-nasal catheter diagnostic procedures involved inserting a tube through the nose and down to the esophagus. The tube was left in place for 24 hours. This test was irritating to the throat, and uncomfortable and awkward for most patients.
Another method uses a small capsule-sized data transmitter that is temporarily attached to the wall of the esophagus during endoscopy. The capsule records pH levels and transmits these data to a pager-sized receiver the person wears. People can maintain their usual diet and activity schedule during the 24 to 48-hour monitoring period. After a few days, the capsule detaches from the esophagus, passes through the digestive tract, and is eliminated through a bowel movement.
Manometry is a technique that measures muscular pressure. It uses a tube containing various openings, which is placed through the esophagus. As the muscular action of the esophagus puts pressure on the tube in various locations, a computer connected to the tube measures this pressure. Manometry is useful for the following situations:
Stool tests may show traces of blood that are not visible. Blood tests for anemia should be performed if bleeding is suspected.
For people with chest pain in which the diagnosis is uncertain, a procedure called the Bernstein test may be helpful, although it is rarely used today. A tube is inserted through the patient's nasal passage. Solutions of hydrochloric acid and saline (salt water) are administered separately into the esophagus. A diagnosis of GERD is established if the acid infusion causes symptoms but the saline solution does not.
Diagnostic tests are often unnecessary in children and adolescents for common GER or GERD. In the absence of more severe symptoms, a conservative approach to diagnosis and treatment is best. In addition to the tests above, other tests that may be used for diagnosis in children include gastroesophagealscintigraphy (milk scan) and esophageal impedance (EI).
Because many illnesses share similar symptoms, a careful diagnosis and consideration of the person's history is key to an accurate diagnosis. The following are only a few of the conditions that could accompany or resemble GERD:
People with heartburn should first try lifestyle and dietary changes. Some suggestions are:
Nearly 75% of people with frequent GERD symptoms have them at night. People with nighttime GERD also tend to experience severe pain. It is very important to take preventive measures before going to sleep, such as:
A reflux board is a device prescribed for use in children who have GER. The board tilts the child upward, to prevent or reduce GER while the child is lying in bed.
Although gum chewing is commonly believed to increase the risk for GERD symptoms, one study reported that it might be helpful. Because saliva helps neutralize acid and contains a number of other factors that protect the esophagus, chewing gum 30 minutes after a meal has been found to help relieve heartburn and even protect against damage caused by GERD. Chewing on anything can help, because it stimulates saliva production.
Acid suppression continues to be the mainstay for treating GERD that does not respond to lifestyle changes and treatment. The aim of drug therapy is to reduce the amount of acid and improve any abnormalities in muscle function of the lower esophageal sphincter, esophagus, or stomach.
Most cases of gastroesophageal reflux (GER) are mild and can be managed with lifestyle changes, over-the-counter medications, and antacids.
People with moderate-to-severe GERD symptoms that do not respond to lifestyle changes, or who are diagnosed at a late stage may be started on medications of varying strength, depending on their complications at diagnosis. The 2 major treatment options are known as the step-up and step-down approaches:
A more recent approach involves an implantable device that includes a ring of titanium magnetic beads that are placed around the lower end of the esophagus. Smaller studies appeared to report a decrease in symptoms and medication usage without significant complications. The device has not been studied in a randomized trial comparing it with other therapies for GERD and its current role is not yet well-defined.
Surgery may be needed in certain circumstances, such as:
Some physicians are recommending surgery as the treatment of choice for many more people with chronic GERD, particularly because minimally invasive surgical procedures are becoming more widely available, and only surgery improves regurgitation. Furthermore, persistent GERD appears to be much more serious than was previously believed, and the long-term safety of using medication for acid suppression is still uncertain.
Nonetheless, anti-GERD procedures have many complications and high failure rates. The true benefit of surgery for patients who have failed medicine therapy is controversial. As with medications, current surgical procedures cannot cure GERD. About 15 to 66% of people still require anti-GERD medications after surgery. Furthermore, about 40% of surgical patients are at risk for new symptoms after surgery (such as gas, bloating, and difficulty swallowing), with most side effects occurring more than a year after surgery. Finally, evidence now suggests that surgery does not reduce the risk for esophageal cancer in high-risk people, such as those with Barrett esophagus. New procedures may improve current results, but at this time people should consider surgical options very carefully with both a surgeon and their primary doctor.
To date, no treatments can reverse the cellular damage after Barrett esophagus has developed, although some procedures are showing promise.
If a person is diagnosed with Barrett esophagus, the doctor will prescribe PPIs to suppress acid. Using these medications may help slow the progression of abnormal changes in the esophagus.
Surgical treatment of Barrett's esophagus may be considered when patients develop high-grade dysplasia of the cells lining the esophagus. Barrett's esophagus alone is not a reason to perform anti- reflux surgery, and is only recommended when other reasons for this surgery are present. See "Surgery" section.
To manage GERD in infants:
The same drugs used in adults may be tried in children with chronic GERD. While some drugs are available over the counter, do not give them to children without physician supervision.
PPIs may also be effective in children. Five different PPIs are approved for use in children and adolescents:
With the exception of Protonix, all of the above PPIs are approved for use in children 1 to 18.
Surgical fundoplication involves wrapping the upper curve of the stomach (fundus) around the esophagus. The goal of this surgical technique is to strengthen the LES. Until recently, surgery was the primary treatment for children with severe complications from GERD because older drug therapies had severe side effects, were ineffective, or had not been designed for children. However, with the introduction of PPIs, many children are able to avoid surgery. It is performed only when medicines are ineffective or for those at risk of severe aspiration.
Surgical fundoplication can be performed laparoscopically through small incisions. Weakening of the LES over the long-term occurs with children as well as adults.
Antacids neutralize acids in the stomach, and are the drugs of choice for mild GERD symptoms. They may also stimulate the defensive systems in the stomach by increasing bicarbonate and mucus secretion. They are best used alone for relief of occasional and unpredictable episodes of heartburn. Many antacids are available without a prescription. The different brands all rely on various combinations of 3 basic ingredients: magnesium, calcium, or aluminum.
Magnesium salts are available in the form of magnesium carbonate, magnesium trisilicate, and most commonly, magnesium hydroxide (Milk of Magnesia). The major side effect of magnesium salts is diarrhea. Magnesium salts offered in combination products with aluminum (Mylanta and Maalox) balance the side effects of diarrhea and constipation.
Calcium carbonate (Tums, Titralac, and Alka-2) is a potent and rapid-acting antacid. It can cause constipation. There have been rare cases of elevated levels of calcium in the blood (hypercalcemia) in people taking large doses of calcium carbonate for long periods of time. This condition can lead to kidney failure and is very dangerous. None of the other antacids has this potential side effect.
Aluminum salts (Amphogel, Alternagel) are also available. The most common side effect of antacids containing aluminum salts is constipation. People who take large amounts of antacids that contain aluminum may also be at risk for calcium loss, which can lead to osteoporosis.
Osteoporosis is a condition that leads to bone density loss, thinning of bone tissue, and increased vulnerability to fractures. Osteoporosis may result from disease, dietary or hormonal deficiency, or advanced age. Getting regular exercise and taking vitamin D and calcium supplements can reduce and even reverse bone density loss.
Although all antacids work equally well, it is generally believed that liquid antacids work faster and are more potent than tablets. Antacids can interact with a number of drugs in the intestines by reducing their absorption. These drugs include tetracycline, ciprofloxacin (Cipro), propranolol (Inderal), captopril (Capoten), and H2 blockers. Interactions can be avoided by taking the drugs 1 hour before, or 3 hours after taking the antacid. Long-term use of nearly any antacid increases the risk for kidney stones.
Proton pump inhibitors (PPIs) suppress the production of stomach acid and work by inhibiting the molecule in the stomach glands that is responsible for acid secretion (the
The standard PPI has been omeprazole (Prilosec), which is now available over the counter without a prescription. Newer prescription oral PPIs include esomeprazole (Nexium), lansoprazole (Prevacid), rabeprazole (AcipHex), pantoprazole (Protonix), and the long-acting PPI dexlansoprazole (Kapidex). All are considered equally effective. Most are taken once per day, sometimes 30 to 60 minutes before a meal, for 8 weeks. Brand, dosage, and timing can be altered by your physician based on response and side effects. Long-term maintenance therapy with a lower dose is sometimes necessary, but may cause low magnesium levels in some people.
Studies report significant heartburn relief in most people taking PPIs. PPIs are effective for healing erosive esophagitis.
In addition to relieving most common symptoms, including heartburn, PPIs also have the following advantages:
People with impaired esophageal muscle action are still likely to have acid breakthrough and reflux, especially at night. PPIs also may have little or no effect on regurgitation or asthma symptoms.
Currently, these drugs are recommended for people with:
These medications have no effect on non-acid reflux, such as bile backup.
Proton-pump inhibitors may cause side effects including headache, diarrhea, constipation, nausea, and itching. However, these side effects are uncommon.
Long-term use of these drugs has been linked to problems caused by poor vitamin or mineral absorption. These include:
There is some evidence that PPIs increase the risk for:
Pregnant women and nursing mothers should discuss the use of PPIs with their health care provider, although recent studies suggest that PPIs do not pose an increased risk of birth defects.
PPIs may interact with certain drugs, including:
Some evidence suggests that acid reflux may contribute to the higher risk of cancer in Barrett's esophagus, but it is not yet confirmed whether acid blockers have any protective effects against cancer in these patients. Moreover, long-term use of PPIs by people with H. pylori may reduce acid secretion enough to cause atrophic gastritis (chronic inflammation of the stomach). This condition is a risk factor for stomach cancer. To compound concerns, long-term use of PPIs may mask symptoms of stomach cancer and thus delay diagnosis. To date, however, there have been no reports of an increased risk of stomach cancer with the long-term use of these drugs.
There had been concerns that the PPIs Prilosec and Nexium might lead to heart attacks or cardiovascular problems. However, after a careful review, the FDA found no evidence of increased cardiovascular risk.
H2 blockers interfere with acid production by blocking or antagonizing the actions of histamine, a chemical found in the body. Histamine encourages acid secretion in the stomach. H2 blockers are available over the counter and relieve symptoms in about half of people with GERD. It takes 30 to 90 minutes for them to work, but the benefits last for hours. People usually take the drugs at bedtime. Some people may need to take them twice a day.
H2 blockers inhibit acid secretion for 6 to 24 hours and are very useful for people who need persistent acid suppression. They may also prevent heartburn episodes. In some studies, H2 blockers improved asthma symptoms in people with both asthma and GERD. However, they rarely provide complete symptom relief for chronic heartburn and dyspepsia, and they have done little to reduce physician office visits for GERD. While PPIs are the initial treatment of choice, H2 blockers may be helpful as a maintenance therapy or bedtime therapy in addition to PPI in some people.
4 H2 blockers are available in the U.S.:
In most cases, these medications have good safety profiles and few side effects. H2 blockers can interact with other drugs, although some less so than others. In all cases, the physician should be made aware of any other drugs a patient is taking. Anyone with kidney problems should use famotidine only under a doctor's direction. More research is needed into the effects of long-term use of these medications.
Some experts are concerned that the use of acid-blocking drugs in people with peptic ulcers may mask ulcer symptoms and increase the risk for serious complications.
These drugs do not protect against Barrett esophagus. Also of concern are reports that long-term acid suppression with these drugs may cause cancerous changes in the stomach in patients who are infected with H. pylori. Research on this question is still ongoing.
Famotidine is removed primarily by the kidney. This can pose a danger to people with kidney problems. The FDA and Health Canada are advising physicians to reduce the dose and increase the time between doses in people with kidney failure. Use of the drug in those with impaired kidney function can affect the central nervous system and may result in anxiety, depression, insomnia or drowsiness, and mental disturbances.
Caution is warranted in pregnant and nursing mothers as the effects are unknown.
Sucralfate (Carafate) protects the mucus lining in the gastrointestinal tract. It works by sticking to an ulcer crater and protecting it from the damaging effects of stomach acid and pepsin. Sucralfate may be helpful for maintenance therapy in people with mild-to-moderate GERD. Other than constipation, the drug has few side effects. Sucralfate interacts with a wide variety of drugs, however, including warfarin, phenytoin, and tetracycline.
Prokinetic drugs help the stomach empty its contents more quickly and strengthen the esophageal sphincter. These are considered second-line access drugs due to side effects. The currently available prokinetic is Metoclopramide (Reglan).
The standard surgical treatment for GERD is
There are 2 primary approaches:
Fundoplication is recommended for people whose condition includes 1 or more of the following:
Fundoplication has little benefit for patients with impaired stomach motility (an inability of the muscles to contract normally).
Until recently, the Nissen fundoplication was the fundoplication procedure most often used for GERD. This is called an open procedure because it requires wide surgical incisions.
The standard invasive fundoplication procedure has been replaced in many cases by a less invasive surgical procedure called laparoscopy. In the operation:
When performed by experienced surgeons, results are equal to those of standard open fundoplication, but with a faster recovery time and fewer side effects.
Overall, laparoscopic fundoplication appears to be safe and effective in people of all ages, even babies. Five years after undergoing laparoscopic fundoplication for GERD, people report a near normal quality of life, and say they are satisfied with their treatment choice. In a 5 year trial, laparoscopic fundoplication provided better relief of symptoms compared to medical management. Laparoscopic surgery also has a low reoperation rate, about 1%.
Laparoscopy is more difficult to perform in certain people, including those who are obese, who have a short esophagus, or who have a history of previous surgery in the upper abdominal area. It may also be less successful in relieving atypical symptoms of GERD, including cough, abnormal chest pain, and choking. In about 8% of laparoscopies, it is necessary to convert to open surgery during the procedure because of unforeseen complications.
There are now different fundoplication procedures.
Many surgeons report that such limited fundoplications help patients start eating and get released from the hospital sooner, and they have a lower incidence of complications (trouble swallowing, gas bloating, and gagging) than the full Nissan fundoplication.
Problems after surgery can include a delay in intestinal functioning, causing bloating, gagging, and vomiting. These side effects usually go away in a few weeks. If symptoms last or start weeks or months after surgery, particularly if there is vomiting, surgical complications are likely. Complications include:
In general, the long-term benefits of these procedures are similar. Fundoplication relieves GERD-induced coughing and other respiratory symptoms in up to 85% of people. Its effect on asthma associated with GERD, however, is unclear. Many people still require anti-GERD medications or experience new symptoms (such as gas, bloating, and trouble swallowing) after surgery. Most of these new symptoms occur more than a year after surgery. Fundoplication does not cure GERD, and evidence suggests that the procedure does not reduce the risk for esophageal cancer in high-risk patients, such as those with Barrett's esophagus. However, fundoplication has very good long-term results, especially when performed by an experienced surgeon, and few people need to have a repeat procedure.
Some studies have reported that 3 to 6% of people need repeat operations, usually because of continuing reflux symptoms and swallowing difficulty (dysphagia). Repeat surgery usually has good success. However, these surgeries can also lead to greater complications, such as injury to the liver or spleen.
Various techniques or devices have been developed to remove the mucus lining of the esophagus. The intention is to remove early cancerous or precancerous tissue (high-grade dysplasia) and allow regrowth of new and hopefully healthy tissue in the esophagus.
Such techniques include photodynamic therapy (PDT), surgical removal of the abnormal lining, or ablation techniques, such as the use of laser, to destroy the abnormal lining. These techniques are done using an endoscope.
People with Barrett's esophagus who are most likely to benefit from these techniques have:
Unfortunately, the benefits do not last in all people. These procedures also carry potential complications, such as swallowing problems, which patients should discuss with their physicians.
Esophagectomy is the surgical removal of all or part of the esophagus. People with Barrett's esophagus who are otherwise healthy are candidates for this procedure if biopsies show they have high-grade dysplasia or cancer. After the esophagus is removed, a new conduit for foods and fluids must be created to replace the esophagus. Alternatives include the stomach, colon, and a part of the small intestine called the jejunum. The stomach is the optimal choice.
A number of endoscopic treatments are being used or investigated for increasing LES pressure and preventing reflux, as well as for treating severe GERD and its complications. Researchers find that endoscopic therapies for GERD may relieve symptoms and reduce the need for antireflux medications, although they are not as effective as laparoscopic fundoplication. Endoscopic procedures are also being done along with fundoplication.
Transoral flexible endoscopic suturing (sometimes referred to as Bard's procedure) uses a tiny device at the end of the endoscope that acts like a miniature sewing machine. It places stitches in 2 locations near the LES, which are then tied to tighten the valve and increase pressure. There is no incision and no need for general anesthesia.
Radiofrequency energy generated from the tip of a needle (sometimes called the Stretta procedure) heats and destroys tissue in problem spots in the LES. It has been shown to reduce symptoms of GERD. People may experience some chest or stomach pain afterward. Few serious side effects have been reported, although there have been reports of perforation, hemorrhage, and even death.
Strictures (abnormally narrowed regions) may need to be dilated (opened) with endoscopy. Dilation may be performed by inflating a balloon in the passageway. About 30% of people who need this procedure require a series of dilation treatments over a long period of time to fully open the passageway. Long-term use of PPIs may reduce the duration of treatments.
Ament PW, Dicola DB, James ME. Reducing adverse effects of proton pump inhibitors. Am Fam Physician. 2012;86(1):66-70.
Arts J, Bisschops R, Blondeau K, Farre R, Vos R, Holvoet L, et al. A double-blind sham-controlled study of the effect of radiofrequency energy on symptoms and distensibility of gastroesophageal junction in GERD. Am J Gastroenterol. 2012;107:222-30.
Blanco FC. Pediatric gastroesophageal reflux disease. Surg Clin North Am. 2012:92(3):541-58.
Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. Plavix Prescribing Information. December 2013. Available online.
Broeders JA, Roks DJ, Jamieson GG, Devitt PG, Baigrie RJ, Watson DI. Five-year outcome after laparoscopic anterior partial versus Nissen fundoplication: four randomized trials. Ann Surg. 2012;255(4):637-42.
Desart K, Rossidis G, Michel M, Lux T, Ben-David K. Gastroesophageal reflux management with the LINX® system for gastroesophageal reflux disease following laparoscopic sleeve gastrectomy. J Gastrointest Surg. 2015 Oct;19(10):1782-6. Epub 2015 Jul 11. PMID: 26162926 www.ncbi.nlm.nih.gov/pubmed/26162926.
FDA. FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Available at: www.fda.gov/Drugs/DrugSafety/ucm290510.htm. Accessed on February 09, 2016.
Filion KB, Chateau D, Targownik LE, Gershon A, Durand M, Tamim H, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut. 2014;63(4):552-8.
Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA. 2011;305(19):1969-77.
Gee DW, Andreoli MT, Rattner DW. Measuring the effectiveness of laparoscopic antireflux surgery: long-term results. Arch Surg. 2008;143:482-87.
Grant AM, Cotton SC, Boachie C, Ramsay CR, Krukowski ZH, Heading RC, et al. Minimal access surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (REFLUX). BMJ. 2013;346:f1908.
Hunter JG, Kahrilas PJ, Bell RC, et al. Efficacy of transoral fundoplication vs omeprazole for treatment of regurgitation in a randomized controlled trial. Gastroenterology. 2015 Feb;148(2):324-333.e5. Epub 2014 Oct 13. PMID: 25448925 www.ncbi.nlm.nih.gov/pubmed/25448925.
Ip S, Bonis P, Tatsioni A, et al. Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease. Evidence Report/Technology Assessment No. 1. (Prepared by Tufts-New England Medical Center. Evidence-based Practice Center under Contract No. 290-02-0022.) Rockville, MD: Agency for Healthcare Research and Quality. December 2005 www.effectivehealthcare.ahrq.gov/ehc/products/165/915/GERD-Update_Disposition-of-Comments_20120104.pdf. Accessed on March 28, 2016.
Khan S, Orenstein SR. Gastroesophageal reflux disease. In: Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. Nelson Textbook of Pediatrics. 20th ed. Philadelphia, PA: Elsevier; 2016:ch 323, 1787-1791.
Katz PO, Gerson LB, Vela MF. Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2013;108:308-28.
Lightdale JR, Gremse DA. Gastroesophageal reflux: management guidance for the pediatrician. Pediatrics. 2013;131(5):e1684-95.
Loots C, Kritas S, van Wijk M, et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. J Pediatr Gastroenterol Nutr. 2014 Aug;59(2):237-43. PMID: 24732026 www.ncbi.nlm.nih.gov/pubmed/24732026.
Pacilli M, Eaton S, McHoney M, et al. Four year follow-up of a randomised controlled trial comparing open and laparoscopic Nissen fundoplication in children. Arch Dis Child. 2014 Jun;99(6):516-21. Epub 2014 Feb 14. PMID: 24532685 www.ncbi.nlm.nih.gov/pubmed/24532685.
Petersen RP, Pellegrini CA, Oelschlager BK. Hiatal Hernia and Gastroesophageal Reflux Disease. In: Townsend: Sabiston Textbook of Surgery. 19th ed. Philadelphia, PA: Elsevier Saunders; 2012:chap 44.
Randel A. AAP releases guideline for the management of gastroesophageal reflux in children. Am Fam Physician. 2014 Mar 1;89(5):395-7. PMID: 24695514 www.ncbi.nlm.nih.gov/pubmed/24695514.
Richter JE, Friedenberg FK. Gastroesophageal reflux disease. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 10th ed. Philadelphia, PA: Elsevier Saunders; 2016:ch 44, 733-754.
Shaheen NJ, Weinberg DS, Denberg TD, et al. Clinical Guidelines Committee of the American College of Physicians. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Intern Med. 2012;157(11):808-16. PMID: 23208168 www.ncbi.nlm.nih.gov/pubmed/23208168.
Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA. 2013;310(6):627-36.
Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Lesie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179:319-326.
U.S. Food and Drug Administration. Drugs: FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). March 2011. Available online.
U.S. Food and Drug Administration. Drug Safety Labeling Changes. May 2012. Available online.
Witteman BP, Conchillo JM, Rinsma NF, et al. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2015 Apr;110(4):531-42. Epub 2015 Mar 31. PMID: 25823768 www.ncbi.nlm.nih.gov/pubmed/25823768.
Reviewed By: Subodh K. Lal, MD, Gastroenterologist with Gastrointestinal Specialists of Georgia, Austell, GA. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Isla Ogilvie, PhD, and the A.D.A.M. Editorial team.